Skip to content

CVBIOCONSULTING

Active Risk: not assessed
Private limited companyfounded 20169 yrs activeZwijnaardsesteenweg 79, 9820 Merelbeke-Melle, BelgiumKBO/BCE: BE 0663.551.462
Summary

CVBIOCONSULTING is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €19k and a net result of €259k. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 12% of 8023 sector peers (fiscal year 2025). The company has been active since 2016 and the Belgian State Gazette contains no insolvency or warning signals.

Checked score

Outside the general model
Model not applicable to financial institutions
The health score weighs liquidity, leverage and margins against norms for trading and manufacturing companies. A bank, insurer or financial holding has a fundamentally different balance-sheet structure, so those ratios, and hence the score, carry no meaning here. That is why we show no financial axes either.
Credit check for your own amount and term

Signals

Two signals. The signal on the left, the evidence on the right.
+raises riskneutral
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 12% of 8023 sector peers (2025).
NBB · sector comparison
Position among 8023 sector peers
Solvency
better than 12%
← weakest strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 07-07-2026, 24 days ahead of the deadline.
NBB · 9 filings
Deviation from the deadline
2025
24 d early
2024
27 d early
2023
7 d early
2022
12 d early
2021
30 d late
2020
30 d late
2019
11 d late
← before the deadline after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Position in the running window
24-09-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

Financials · fiscal year 2025, micro schema

Source amounts without an identifiable currency are assumed to be EUR.

Equity
€19k=
2024 · €19k
2018: €109k 2019: €249k 2020: €249k 2021: €22k 2022: €22k 2023: €19k 2024: €19k
2018 → 2025
Net result
€259k▼ 14.7%
2024 · €304k
2018: €83k 2019: €128k 2020: €128k 2021: €95k 2022: €139k 2023: €225k 2024: €304k
2018 → 2025
Total assets
€359k▲ 0.3%
2024 · €358k
2018: €143k 2019: €299k 2020: €299k 2021: €133k 2022: €213k 2023: €317k 2024: €358k
2018 → 2025
Solvency
5.2%=
2024 · 5.2%
2018: 75.9% 2019: 83.3% 2020: 83.3% 2021: 16.6% 2022: 10.4% 2023: 5.9% 2024: 5.2%
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise ▼ fall
Line20212022202320242025Trend
Equity€22k-€22k▲ 1.3%€19k▼ 16.6%€19k=€19k=
Operating result€123k-€183k▲ 49.4%€299k▲ 63.2%€404k▲ 35.2%€346k▼ 14.4%
Net result€95k-€139k▲ 46.9%€225k▲ 61.6%€304k▲ 35.1%€259k▼ 14.7%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
€0€200k€400kOperating result 2021: €123k€123kNet result 2021: €95k€95kOperating result 2022: €183k€183kNet result 2022: €139k€139kOperating result 2023: €299k€299kNet result 2023: €225k€225kOperating result 2024: €404k€404kNet result 2024: €304k€304kOperating result 2025: €346k€346kNet result 2025: €259k€259k20212022202320242025€0€200k€400kOperating result 2023: €299k€299kNet result 2023: €225k€225kOperating result 2024: €404k€404kNet result 2024: €304k€304kOperating result 2025: €346k€346kNet result 2025: €259k€259k202320242025
The operating result falls in 2025; 2025 is 14% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €359k
Fixed assets €4k ▼ 2.9%
Current assets €355k ▲ 0.4%
Equity and liabilities €359k
Equity €19k =
Debt €340k ▲ 0.3%
Debt's share of the balance-sheet total stays at 94.8%.
Key figures and ratios
2025 value · change against 2024
ROA
72.3%
2024 · 85.0%
Debt ≤ 1 year
€338k
2024 · €339k
Income taxes
€85k
2024 · €99k
A ratio outside any meaningful range has been withheld (balance sheet total €359k, equity €19k).
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 38 lines
Balance sheet Code20242025
Assets
Total assets20/58€358k€359k
Fixed assets21/28€4k€4k
Tangible fixed assets22/27€4k€4k
Furniture and vehicles24€206-
Leasing and similar rights25€495-
Other tangible fixed assets26€3k€4k
Current assets29/58€354k€355k
Amounts receivable within one year40/41€230k€42k
Trade receivables40€230k€42k
Cash at bank and in hand54/58€120k€308k
Deferred charges and accrued income490/1€4k€5k
Equity and liabilities
Total equity and liabilities10/49€358k€359k
Equity10/15€19k€19k=
Contributions10/11€19k€19k=
Amounts payable17/49€339k€340k
Amounts payable within one year42/48€339k€338k
Trade debts44€910€2k
Suppliers440/4€910€2k
Taxes, remuneration and social security45€34k€113k
Taxes450/3€34k€108k
Remuneration and social security454/9-€4k
Other amounts payable47/48€304k€223k
Accrued charges and deferred income492/3€17€3k
Income statement Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€2k€1k
Other operating charges640/8€975€1k
Gross operating margin9900€407k€348k
Operating profit (loss)9901€404k€346k
Financial income75/76B€1k€491
Recurring financial income75€1k€491
Financial charges65/66B€2k€2k
Recurring financial charges65€2k€2k
Profit (loss) for the period before taxes9903€403k€344k
Income taxes67/77€99k€85k
Profit (loss) for the period9904€304k€259k
Profit (loss) for the period to be appropriated9905€304k€259k
Appropriation of the result
Profit (loss) to be appropriated9906€304k€259k
Profit to be distributed694/7€304k€259k
Return on contributions (dividend)694€304k€259k

The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 31-07-2027
2026
07-07
NBB filing Annual accounts filed
fiscal year 2025 · micro schema
04-03
State Gazette act Board meeting · Director appointment
Permanent representative
2025
04-07
NBB filing Annual accounts filed
fiscal year 2024 · micro schema
2024
31-12
Financial Highest result since 2018net €304k ▲35.1%
Operating result €404k, net result €304k, both a record.
24-07
NBB filing Annual accounts filed
fiscal year 2023 · micro schema
2023
19-07
NBB filing Annual accounts filed
fiscal year 2022 · micro schema
2022
30-08
NBB filing Annual accounts filed
fiscal year 2021 · micro schema · 30 days late
2021
30-08
NBB filing Annual accounts filed
fiscal year 2020 · micro schema · 30 days late
2020
11-08
NBB filing Annual accounts filed
fiscal year 2019 · micro schema · 11 days late
2019
31-12
Financial Equity above €200kEq €249k ▲129%
2 profitable years in a row build equity to €249k.
25-09
NBB filing Annual accounts filed
fiscal year 2018 · micro schema · 56 days late
2018
25-09
NBB filing Annual accounts filed
fiscal year 2017 · micro schema · 56 days late
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Merelbeke-Melle · 1 establishment unit since 2016
establishment The establishment unit on the map
Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Zwijnaardsesteenweg 799820 Merelbeke-Melle
Ground area
469 m²
Building footprint
94 m²
Volume, LiDAR
712 m³
Parcel 44412B0185/00G002, Flanders · tallest building 11.5 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
CVBIOCONSULTING
Zwijnaardsesteenweg 79, 9820 Merelbeke-MelleHoldings
since 20162.257.922.250
1 parcel
Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
44412B0185/00G002 Flanders 469 m² 1 · 94 m² 11.5 m · 3 fl.
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Structure & network

Connections & network

1 connected company
Linked via shared directors
Confo Therapeutics
Shared director

Similar companies · same sector, comparable size

Of 24,725 companies in sector 64210 we hold annual accounts for 19,762. 7,163 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Company data · Crossroads Bank

Identification
Legal formPrivate limited company
Founded28-09-2016
Fiscal year end31-12
Activities, NACEBEL 2025
64210Activities of holding companies
Sources
Crossroads Bank for EnterprisesNational Bank · 9 filingsAddress and cadastre registers

Scores and ratios are computed by Checked and are not a credit decision.